# IN THE CLAIMS (37 CFR 1.121 Revised)

Cancel claims 7-9.

1. (currently amended) A compound of the Formula I

$$X_{m}$$
 $N$ 
 $C(CX^{1}X^{2})_{n}CO_{2}H$ 

or the pharmaceutically acceptable salts thereof, wherein: X is

$$R^2$$
  $R^5$  , or  $R^1$   $R^5$   $R^5$   $R^4$   $R^5$   $R^7$   $R^7$   $R^7$   $R^7$   $R^7$   $R^7$   $R^7$ 

each n is independently 1 to 3 inclusive;

 $\rm X^1$  and  $\rm X^2$  are independently hydrogen or C<sub>1</sub>-C<sub>8</sub> alkyl, or -(CH<sub>2</sub>)<sub>V</sub>-Z;

y is 0 to 4 inclusive;

Z is hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>1</sub>-C<sub>8</sub> perfluoroalkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl,-OH, -OC<sub>1</sub>-C<sub>8</sub> alkyl, -SC<sub>1</sub>-C<sub>8</sub> alkyl,-SO<sub>3</sub>H, -CO<sub>2</sub>H,

-N(C<sub>1</sub>-C<sub>8</sub>alkyl)<sub>2</sub>, -NCC<sub>1</sub>-C<sub>8</sub> alkyl, guanidinyl, thienyl, imidazolyl, thiazolyl, or indolyl, phenyl, substituted phenyl wherein 1-4 substituents are present each independently selected from a group consisting of halogen, -OH, -CF3, -NO2, -NH2, -NH(C1-C6alkyl), N(C1-C6alkyl)2, C1-C6 alkyl, -OC1-C6 alkyl, -CN, -CF3, -CO2H, and CO2C1-C6 alkyl, naphthyl, substituted naphthyl wherein a substituent is selected from a group consisting of halogen, -OH, -CF3, -NO2, -NH2, -NH(C1-C6alkyl), N(C1-C6alkyl)2, C1-C6 alkyl, -OC1-C6 alkyl, -CN, -CF3, -CO2H, and CO2C1-C6 alkyl;

R<sup>1</sup> [and R<sup>2</sup> are independently] is C<sub>1</sub> -C<sub>8</sub>alkyl or -(CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>6</sub>cycloalkyl,

-(CH<sub>2</sub>)<sub>n</sub>-phenyl, and R<sup>2</sup> is C<sub>4</sub> -C<sub>8</sub>alkyl or -(CH<sub>2</sub>)<sub>n</sub>-C<sub>3</sub>-C<sub>6</sub>cycloalkyl,

-(CH<sub>2</sub>)<sub>n</sub>-phenyl, or R<sup>1</sup> and R<sup>2</sup> taken together with the nitrogen atom to which they are attached to form a cyclic structure selected from

$$-N$$
 $R^3$ 
,  $-N$ 
 $(CH_2)_m$ 
,

$$\mathbb{R}^3$$
  $\mathbb{R}^4$  , or  $\mathbb{R}^3$   $\mathbb{R}^4$  ;

where R<sup>3</sup> and R<sup>4</sup> independently are hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, (CH<sub>2</sub>)<sub>n</sub>-phenyl, or (CH<sub>2</sub>)<sub>n</sub>-cycloalkyl; R<sup>5</sup> is hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, halogen or -CF<sub>3</sub>; and each m is 2 to 8 inclusive.

### 2. (currently amended) The compounds:

(Z) [5-(4-Diethylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;

(Z) [5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;

(Z) [5-(4-Dipropylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid:

(Z) [5-(4-Diisobutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic

(Z) [5-(4-Dipentylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yll-acetic acid:

(Z) (5-{4-[Bis-(3-methyl-butyl)-amino]-benzylidene}-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic acid;

(Z) [5-(4-Azepan-1-yl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;

(Z) [5-(4-Dihexylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;

(Z) {5-[4-(Methyl-octyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid; or

(Z) {5-[4-(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid.

#### 3. (currently amended) The compounds:

(Z) {5-[4-(Cyclopropylmethyl-propyl-amino)-benzylidene]-4-oxo-2-thioxothiazolidin-3-yl}-acetic acid;

(Z) {5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;

(Z) {5-[4-(Methyl-phenethyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;

(Z) {5-[4-(3-Aza-spiro[5.5]undec-3-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;

(Z) 3-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid:

(Z) {5-[4-(Butyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid:

(Z) {5-[4-(Butyl-ethyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;

- (Z) {5-[4-(Benzyl-butyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
- (Z) [5-(4-Dioctylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;
- (Z) 4-{5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-

### butyric acid;

- (Z) 3-{5-[4-(Hexyl-methyl-amino)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
- (Z) 3-[5-(4-Dipentylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid:
- (Z) 4-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-butyric acid:
- (Z) 4-[5-(4-Dipentylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-butyric acid:
- (Z) 2-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid:
- (Z) 2-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-3-phenyl-propionic acid;
- (Z) 2-[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-3-(3H-imidazol-4-yl)-propionic acid;
- (Z) {5-[4-(Hexyl-methyl-amino)-naphthalen-1-ylmethylene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
- (Z) [4-Oxo-5-(4-pyrrolidin-1-yl-benzylidene)-2-thioxo-thiazolidin-3-yl]-acetic acid;
- (Z) {5-[4-(4-Butyl-piperazin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
- (Z) (4-Oxo-5-{4-[4-(3-phenylpropyl)piperidine-1-yl]-benzylidene}-2-thioxothiazolidin-3-yl)-acetic acid;
- (Z) {5-[4-(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
- (Z) 3-{5-[4-(3-Aza-spiro[5.5]undec-3-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
- (Z) 3-[4-Oxo-5-(4-perhydro-azepin-1-yl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-propionic acid;
- (Z) 4-{5-[4-(3-Aza-spiro[5.5]undec-3-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;
- (Z) {4-Oxo-5-[4-(4-propyl-piperidin-1-yl)-benzylidene]-2-thioxo-thiazolidin-3-yl}-acetic acid;
- (Z) 3-{4-Oxo-5-[4-(4-propyl-piperidin-1-yl)-benzylidene]-2-thioxo-thiazolidin-3-yl}-propionic acid;
- (Z) 4-{4-Oxo-5-[4-(4-propyl-piperidin-1-yl)-benzylidene]-2-thioxo-thiazolidin-3-yl}butyric acid;
- (Z) [5 (1-Butyl-1,2,3,4-tetrahydro-quinolin-6-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl]-acetic-acid;
- (Z) 3-{5-[(4aS,8aR)-4-(octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-thioxothiazolidin-3-yl}-propionic acid;
- (Z) 4-{5-[(4aS,8aR)-4-(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-thioxothiazolidin-3-yl}-butyric acid;
- (Z) [4-Oxo-5-(4-piperidin-1-yl-benzylidene)-2-thioxo-thiazolidin-3-yl}acetic acid;
- (Z) 3-{5-[(4aS,8aS)-4-(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
- (Z) 4-[4-Oxo-5-(4-perhydro-azepin-1-yl-benzylidene)-2-thioxo-thiazolidin-3-yl]-butyric acid;
- (Z) 4-{5-[(4aS,8aS)-4-(Octahydro-isoquinolin-2-yl)-benzylidene]-4-oxo-2-thioxothiazolidin-3-yl}-butyric acid;

- (Z) 3-[4-Oxo-5-(4-piperidine-1-yl-benzylidene)-2-thioxo-thiazolidin-3-yl]propionic acid;
- (Z) 4-[4-Oxo-5-(4-piperidine-1-yl-benzylidene)-2-thioxo-thiazolidin-3-yl}butyric acid:
- (Z) {5-[(4-azocan-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;
- (Z) {5-[4-(4-Ethyl-4-methyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
- (Z) 3-{5-[4-(4-Ethyl-4-methyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxothiazolidin-3-yl}-propionic acid;
- (Z) {5-[4-(4-Cyclohexylmethyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxothiazolidin-3-yl}-acetic acid;
- (Z) [5-(1-Butyl-2,3-dihydro-1H-indol-5-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic acid;
- (Z) 4-{5-[4-(4-Ethyl-4-methyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;
- (Z) 3-{5-[4-(4-Cyclohexylmethyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxothiazolidin-3-yl}-propionic acid;
- (Z) 3-{5-[4-(4-Benzyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
- (Z) {5-[4-(4-Benzyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid:
- (Z) 4-[4-Oxo-5-(4-azocan-1-yl-benzylidene)-2-thioxo-thiozolidine-3-yl]butyric acid;
- (Z) 4-{5-[4-(4-Benzyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;
- (Z) 4-{5-[4-(4-Cyclohexylmethyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxothiazolidin-3-yl}-butyric acid;
- (Z) 3-[4-Oxo-5-(4-perhydro-azacin-1-yl-benzylidene)-2-thioxo-thiazolidine-3-yl]propionic acid;
- (Z) 3 [5 (1-Butyl-1,2,3,4-tetrahydro-quinolin-6-ylmethylene) 4-oxo-2-thioxe-thiazolidin-3-yl]-propionic acid;
- (Z) 4-[5-(1-Butyl-1,2,3,4-tetrahydro-quinolin-6-ylmethylene) 4-oxo-2-thioxothiazolidin-3-yl]-butyric-acid;
- (Z) {5-[4-(4-Hexyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
- (Z) 3-{5-[4-(4-Hexyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
- (Z) 4-{5-[4-(4-Hexyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;
- (Z) {5-[4-(4-Butyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
- (Z) 3-{5-[4-(4-Butyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
- (Z) 4-{5-[4-(3-Butyl-piperidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid;
- (Z) {5-[4-(3-Pentyl-pyrrolidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid;
- (Z) 3-{5-[4-(3-Pentyl-pyrrolidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid;
- (Z) 4-{5-[4-(3-Pentyl-pyrrolidin-1-yl)-benzylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-butyric acid.
- (original) A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 1.

- (original) A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 3.
- (currently amended) A method of treating Alzheimer's disease, the method comprising administering to a patient having Alzheimer's disease a therapeutically effective amount of a compound of Claim 4 2.

## 7-9 (CANCELED)

- 10. (withdrawn) A method of imaging amyloid deposits, the method comprising the steps of:
  - a. introducing into a patient a detectable quantity of a labeled compound of Claim 1;
  - allowing sufficient time for the labeled compound to become associated with amyloid deposits; and
  - c. detecting the labeled compound associated with the amyloid deposits.
- (withdrawn) A method of imaging amyloid deposits, the method comprising the steps of:
  - a. introducing into a patient a detectable quantity of a labeled compound of Claim 3;
  - allowing sufficient time for the labeled compound to become associated with amyloid deposits; and
  - c. detecting the labeled compound associated with the amyloid deposits.
- 12. (withdrawn) A method of imaging amyloid deposits, the method comprising the steps of:
  - a. introducing into a patient a detectable quantity of a labeled compound of Claim 4;
  - b. allowing sufficient time for the labeled compound to become associated with amyloid deposits; and
  - c. detecting the labeled compound associated with the amyloid deposits.
- 13. (withdrawn) The method of Claim 11 wherein the patient has or is suspected to have Alzheimer's disease.
- 14. (withdrawn) The method of Claim 12 wherein the patient has or is suspected to have Alzheimer's disease.
- 15. (withdrawn) The method of Claim 13 wherein the patient has or is suspected to have Alzheimer's disease.

- 16. (withdrawn) The method of Claim 11 wherein the labeled compound is a radiolabeled compound.
- 17. (withdrawn) The method of Claim 12 wherein the labeled compound is a radiolabeled compound.
- 18. (withdrawn) The method of Claim 13 wherein the labeled compound is a radiolabeled compound.
- 19. (withdrawn) The method of Claim 11 wherein the labeled compound is detected using MRI.
- (withdrawn) The method of Claim 12 wherein the labeled compound is detected using MRI.
- (withdrawn) The method of Claim 13 wherein the labeled compound is detected using MRI.
- 22. (original) A pharmaceutical composition comprising a compound of Claim 1 together with an excipient, diluent, or carrier therefor.
- 23. (original) A pharmaceutical composition comprising a compound of Claim 3 together with an excipient, diluent, or carrier therefor.
- 24. (currently amended) A pharmaceutical composition comprising a compound of Claim [4]2 together with an excipient, diluent, or carrier therefor. sulfone; and